A 56-year-old man with long-standing type 2 diabetes and albuminuric CKD (ACR 80 mg/mmol) is on maximal ACE inhibitor and has good blood pressure control. According to Diabetes Canada and cardiorenal guidelines, which additional therapy is preferred to reduce renal and cardiovascular risk?